FDA Seeks Schedule I Ban on Synthetic Kratom 7-OH

U.S. health officials, led by the FDA and HHS, are seeking to restrict 7-hydroxymitragynine (7-OH), a highly concentrated and synthetic derivative of kratom, due to its potent opioid-like effects and increasing reports of overdoses, poisonings, and emergency room visits. The proposed federal action targets concentrated synthetic forms of 7-OH, commonly found in products sold at gas stations and vape shops, while excluding natural kratom leaf products. 7-OH is recommended for classification as a Schedule I drug, alongside heroin and LSD, based on its perceived lack of medical use and significant abuse risk. Health officials argue the move is needed to prevent a new opioid crisis, while some users and industry groups caution against conflating natural kratom with its dangerous derivatives. There is ongoing debate about the risks and benefits, with advocates noting a lack of definitive evidence tying 7-OH alone to fatal overdoses. The DEA will review the recommendation, solicit public comments, and make a final decision on scheduling.